MoS2-CuO heteronanocomposites were then loaded with bovine serum albumin (BSA) and immunoadjuvant imiquimod (R837) on its surface to further form MoS2-CuO@BSA/R837 (MCBR) nanoplatforms, which had an excellent ability to eliminate the primary tumor and release tumor-associated antigens (TAAs). This evidence concerns the gene ALB and neoplasm.